The Relationship Between the HALP Score and Gastric Cancer Prognosis
Journal Title: Journal of European Internal Medicine Professionals (JEIMP) - Year 2023, Vol 1, Issue 4
Abstract
Background: Gastric adenocarcinoma is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths. As most patients are diagnosed in the advanced stage of the disease, the prognosis is dismal. Therefore, researchers have developed various scoring systems to predict prognostic factors. One of these is the HALP scale, which consists of hemoglobin, albumin, lymphocytes and platelets. This study aims to assess the utility of the HALP score as a prognostic tool in predicting the clinical outcomes of patients with gastric adenocarcinoma. Methods: A retrospective review of patients who underwent gastrectomy for gastric cancer between 2018 and 2021 in the Department of Surgical Oncology, Gulhane Medical School Training and Research Hospital, University of Health Sciences. A total of 158 patients who underwent surgery for the diagnosis of gastric adenocarcinoma were included in the study. Hemoglobin, albumin, lymphocytes and platelet values were obtained from patient files. HALP scores were calculated and correlations with clinicopathologic factors were investigated. Results: We found a significant negative correlation between the HALP score and T stage and N stage. Increasing the HALP score increases the likelihood of early-stage disease (p = 0.008 and p = 0.001). We found a significant negative correlation between the HALP score and the number of metastatic lymph nodes and tumor diameter ( p < 0.001 and p < 0.001). One unit increase in HALP score leads to a 4.7 unit decrease in tumor diameter and a 14.8 unit decrease in metastatic lymph node count. Conclusion: This study provides insights into the potential utility of the HALP score in predicting clinical outcomes for gastric cancer patients. While these findings are promising, research with large patient data is essential to validate the prognostic value of the HALP score and determine its clinical applicability. The HALP score may assist clinicians in risk stratification and therapeutic decision-making, and ultimately contributing to improved patient outcomes in the management of gastric cancer.
Authors and Affiliations
Gökhan Giray Akgül
Keywords
Related Articles
- EP ID EP733915
- DOI https://doi.org/10.5281/zenodo.10019807
- Views 46
- Downloads 1
The Assessment of Stroke Patients Using the Functional Independence Measurement Scale
Background: The objectives of this study are; evaluating hemiplegic patients using the "Functional Independence Measurement Scale (FIM)", assessing the long-term daily life activities of patients receiving and not receiv...
Can the Monocyte/HDL Ratio be used as A Marker to Predict Fatty Liver and Its Stages?
Background: Our study aims to determine whether the monocyte/HDL ratio is a marker that can be used to predict the presence and stage of non-alcoholic fatty liver. Material and Method: Patients aged 18-65 years withou...
Is Obesity an Obstacle to Being A kidney Donor? Experiences from A High-Volume Center
Background: Donor obesity is considered a relative contraindication to kidney donation by most transplant centers because of concerns about short-term and long-term morbidity and mortality. In this study, the impact of k...
The Frequency of ANA-positivity and Inflammatory Markers in COVID-19
Background: Immune system activation plays an important role in pathogenesis and mortality in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The inflammatory response during the disease is caused...
Dyslipidemia and Kidney: An Updated View
Dyslipidemia is a common concern in various kidney-related conditions, including chronic kidney disease, nephrotic syndrome, kidney transplant patients, and those undergoing dialysis. Dyslipidemia is a significant risk f...